Calgary-based pre-clinical stage pharmaceutical development biotechnology company Marvel Biosciences Corporation and its wholly owned subsidiary Marvel Biotechnology Inc, have announced the extension of its collaboration with Drs. Julie Le Merrer and Jerome Becker, lead investigators at the iBraiN Institute in Tours France. Building upon the promising results using MB204 in an autism model earlier this year, we now aim to test our lead asset in a mouse model of Rett syndrome.
July 25 (Reuters) - The European Medicines Agency has backed the use of Novo Nordisk's (NOVOb.CO), opens new tab Wegovy to lower major heart risks and strokes in overweight or obese adults without diabetes, the Danish drugmaker said on Thursday.
Almac Pharma Services has successfully completed its first U.S. FDA inspection of its commercial manufacturing facility in Charnwood, England.
Veeva Systems has announced that Neuraxpharm will use Veeva Vault QualityDocs and Veeva Vault Training to advance its quality operations, which will help Neuraxpharm achieve greater oversight and inspection readiness while improving collaboration across its network of over 100 contract development and manufacturing organizations (CDMOs).
Following last week’s R&D day, argenx continues to demonstrate that its flagship drug, FcRn inhibitor Vyvgart, has plenty of room to grow in its inaugural generalized myasthenia gravis (gMG) indication.
While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus (RSV) drug, the near-term expected approval of a pair of new filling lines is giving the French pharma assurance that its Sanofi-partnered antibody Beyfortus can breach the billion-dollar threshold before the year is out.
Just three months after scoring an accelerated FDA approval for Ojemda, Day One Biopharmaceuticals is teaming up with another fellow oncology specialist to grow the medicine's global reach.
While Roche touted sales and market share increases for eye disease drug Vabysmo on Thursday, there is evidence of a slowdown of its momentum as it battles Regeneron and Bayer’s powerhouse Eylea franchise.
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a revamp of perioperative clinical trial designs in resectable non-small cell lung cancer (NSCLC) to include assessment of the contribution of each treatment phase.
Roche has punted a Pompe disease gene therapy from its pipeline after weighing up the competitive landscape. The Swiss drugmaker made the change in a second-quarter update that also featured news of TIGIT trial closures and a commitment not to make “huge cuts” to the organization.